Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Nomenclature01:17

Drug Nomenclature

1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K
Bioequivalence: Overview01:16

Bioequivalence: Overview

892
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
892
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.2K
Prodrugs01:30

Prodrugs

2.3K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.3K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing bioactivity of 3D-printed porous scaffolds with self-assembling peptide hydrogels for cartilage tissue engineering.

3D printing in medicine·2026
Same author

Transdifferentiated BLaER1 cells as a genetically-tractable model to study the interaction of pathogenic fungi with macrophages.

Disease models & mechanisms·2026
Same author

p1/s1, a 3'-nucleotidase/nuclease, allows Leishmania major to circumvent host innate immune response mechanisms.

PLoS pathogens·2026
Same author

Defining core competencies for advanced therapy medicinal products translation.

Frontiers in digital health·2026
Same author

Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148].

Neoplasia (New York, N.Y.)·2026
Same author

Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer.

Scientific reports·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K

The Tailored Biosimilar Approach: Expectations and Requirements.

Elena Guillen1, Sean Barry2,3, Nils Jost4,5

  • 1Department of Clinical Pharmacology, Hospital Clínic, Barcelona, Spain.

Drugs
|April 1, 2025
PubMed
Summary
This summary is machine-generated.

The tailored biosimilar approach reduces the need for clinical efficacy studies (CES) by relying on advanced physicochemical and functional testing. This streamlines biosimilar drug approval, ensuring safety and efficacy with fewer clinical trials.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Related Experiment Videos

Last Updated: May 5, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Area of Science:

  • Biopharmaceutical Science
  • Regulatory Science
  • Drug Development

Background:

  • Current biosimilar approval relies on physicochemical, functional, pharmacokinetic data, and clinical efficacy studies (CES).
  • Regulatory thinking is evolving towards a tailored biosimilar approach, minimizing reliance on CES.
  • Limitations exist in using CES for definitive regulatory decision-making in biosimilarity.

Purpose of the Study:

  • To discuss the tailored biosimilar approach as an evolution in regulatory strategy.
  • To explore the predictive value of physicochemical and functional data for clinical performance.
  • To outline future requirements and exceptions for biosimilar approvals.

Main Methods:

  • Review of current regulatory requirements for biosimilar approval.
  • Analysis of physicochemical and functional testing as predictors of clinical outcomes.
  • Examination of pharmacokinetic study designs for biosimilarity assessment.
  • Identification of specific scenarios necessitating additional clinical evidence.

Main Results:

  • Physicochemical and functional data, combined with pharmacokinetic studies, can sufficiently establish biosimilarity in most cases.
  • The tailored approach can streamline biosimilar development and regulatory review.
  • CES may not always be necessary, depending on product characterization and known risks.

Conclusions:

  • The tailored biosimilar approach represents a significant advancement in regulatory science.
  • Robust analytical data can often replace extensive clinical trials for biosimilar approval.
  • Specific exceptions exist where additional clinical data remain essential for ensuring patient safety and product efficacy.